Can you lower Lp(a)?

Genes explain about 70% to over 90% of the variation in Lp(a) [9], which leaves little room for lifestyle. The EAS summarizes the diet data [1]:

• Replacing saturated fat with carbohydrate or unsaturated fat raises Lp(a) by about 10% to 15%.
• A low-carbohydrate, high-saturated-fat diet lowers it by about 15%.

These are small changes, and they move in the opposite direction to LDL cholesterol and ApoB, which matter more for most people. A diet that lowers Lp(a) slightly by raising LDL is not a good trade. Kaur and colleagues report the same pattern, with saturated fat replacement raising Lp(a) about 15% [10].

The honest answer to "how to reduce Lp(a) naturally" is that no food, diet or exercise plan has been shown to lower it enough to matter. What lifestyle does do is lower the other risks that add to Lp(a): LDL cholesterol, blood pressure, blood sugar and smoking. Protocols such as longevity focus and Attia-style longevity track those.

In 5,256 patients, the statin-to-placebo ratio of Lp(a) change was 1.11, meaning about 11% more rise on a statin, and atorvastatin raised it more than pravastatin [2]. A larger pooled analysis of 29,069 patients found no significant average change when statins were started [11], and Kaur and colleagues judge the effect not clinically significant [10].

What matters more is that Lp(a) keeps predicting risk on a statin. Lp(a) of 50 mg/dL or more carried a 43% higher event risk in statin users [11], even among those with the lowest achieved LDL cholesterol [12]. That is why the ESC/EAS 2025 update strongly encourages high-intensity statins in people with high Lp(a), not fewer statins [3].

The table compiles each therapy's effect from the trial or review that measured it [2][4][10][13][14][1][15][16][17][18][19], with status from the sponsor and ClinicalTrials.gov [6][7][20][8].

Available now

• PCSK9 inhibitors. In FOURIER, evolocumab lowered Lp(a) by a median 26.9%, and people with above-median Lp(a) had a 23% drop in coronary events against 7% for those below [4]. They are approved to lower LDL, not Lp(a).
• Lipoprotein apheresis. A procedure that filters Lp(a) and LDL out of the blood. It lowered Lp(a) 68.1% per session in a German study, about 30% averaged over time [10]. In the US, it has an FDA indication for people with familial hypercholesterolemia and heart or artery disease whose Lp(a) stays at 60 mg/dL (about 150 nmol/L) or more and LDL at 100 mg/dL or more on maximal therapy [14].
• Niacin. Lowers Lp(a) up to about 30% [10], but in 25,673 people it did not reduce major vascular events and raised serious side effects such as diabetes problems and bleeding [13]. The EAS does not recommend it for Lp(a) [1].

In trials

Pelacarsen, olpasiran, lepodisiran and zerlasiran are injections that stop the liver from making apo(a); muvalaplin is a daily pill that blocks assembly of the Lp(a) particle [5].

• Pelacarsen (Novartis). Lp(a)HORIZON enrolled 8,323 people with heart disease and Lp(a) of 70 mg/dL or more. It did not meet its primary endpoint of fewer cardiovascular deaths, heart attacks, strokes and urgent coronary procedures; full data are due at a medical meeting [6][21]. Reviewers point to late treatment, advanced disease, strong background therapy and the depth of Lp(a) lowering as possible reasons [22].
• Olpasiran (Amgen). Lowered Lp(a) 70.5% to over 97% in phase 2 [16]. OCEAN(a)-Outcomes has 7,297 participants, with primary completion estimated for March 2028 [7].
• Lepodisiran (Lilly). Lowered Lp(a) 93.9% in phase 2, and a single 400 mg dose still gave a time-averaged 88.5% reduction over almost a year [17]. ACCLAIM-Lp(a) plans about 17,300 participants, due March 2029 [20].
• Muvalaplin (Lilly). The only pill, lowering Lp(a) 47.6% to 85.8% in phase 2 [19]. MOVE-Lp(a) is recruiting about 10,450 people, due March 2031 [8].
• Zerlasiran (Silence Therapeutics). Lowered Lp(a) 81.3% to 85.6% in phase 2 [18]. When we checked ClinicalTrials.gov in October 2026 we found no registered phase 3 outcome trial.

Genetic modeling suggests a large absolute drop, about 101.5 mg/dL, is needed to match the benefit of lowering LDL cholesterol by 1 mmol/L [23]. The siRNA drugs come closer to that than pelacarsen did, which is why their trials still matter.

Lp(a) multiplies baseline risk, so taking weight off the rest of the scale shrinks its absolute effect. The EAS notes that an Lp(a) of about 250 nmol/L roughly doubles risk whatever your starting point [1]. What guidelines recommend:

• Lower LDL cholesterol and ApoB harder. The ESC/EAS 2025 update says more intensive LDL lowering is reasonable and high-intensity statins should be strongly encouraged [3]. HEART UK suggests non-HDL cholesterol below 100 mg/dL (2.5 mmol/L)2.5 mmol/L (100 mg/dL) [24]. Track ApoB and LDL cholesterol.
• Start earlier. The NLA and ACC/AHA advise early, more intensive risk factor management for elevated Lp(a), whatever the LDL level [14][25].
• Control the other risk factors. Blood pressure, diabetes and smoking add to Lp(a) risk; the EAS recommends treating them early according to overall risk [1]. See HbA1c and triglycerides.
• Consider a PCSK9 inhibitor if LDL stays high. It lowers both LDL and, modestly, Lp(a), and people with higher Lp(a) gained more absolute benefit in FOURIER [4].
• Test your family [26].

Decisions about medicines belong with your clinician, who can weigh your full risk picture.

Niacin is the best-studied option, and the evidence is negative: in HPS2-THRIVE, extended-release niacin did not reduce major vascular events and increased serious problems with diabetes control, infection and bleeding [13]. The EAS does not recommend it for Lp(a) [1]. We found no outcome trial for any other supplement marketed for Lp(a).

If you see a product promising to lower Lp(a), compare its claim with the numbers in the table above, and ask whether it was tested in a randomized trial with heart attacks or strokes as the outcome.